LENZ Therapeutics, Inc.

LENZ

Held by 7 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

7 funds opened new positions. Short interest: 55.3% of float.

Catalysts

Phase 2Q4 2015PRX-100PresbyopiaNCT02554396

Primary: binocular assessment of uncorrected near visual acuity (day 1)Enrollment:20/20Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2018Aceclidine+tropicamide combinationPresbyopiaNCT03201562

Primary: Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye (1 hour post-treatment)Enrollment:58/58Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2022Aceclidine+Brimonidine combination ophthalmic solutionPresbyopia, Refractive Errors, Eye DiseasesNCT05294328

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision (1 hour post treatment)Enrollment:68/68Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2022Aceclidine+Brimonidine combination ophthalmic solutionPresbyopia, Refractive Errors, Eye DiseasesNCT05431543

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision (1 hour post treatment)Enrollment:59/59Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2023Aceclidine+Brimonidine combination ophthalmic solutionPresbyopia, Near Vision, Refractive ErrorNCT05728944

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision (3 hours post-treatment in the study eye on Day 1)Enrollment:229/229Sites: 17RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2023Aceclidine+Brimonidine combination ophthalmic solutionPresbyopia, Refractive Error, Eye DiseasesNCT05656027

Phase 3Q1 2024Aceclidine+Brimonidine combination ophthalmic solutionPresbyopia, Near Vision, Refractive ErrorNCT05753189

Primary: Number of Participants With at Least One Treatment-Related TEAE (7 visits over a total duration of approximately 28 weeks)Enrollment:362/362Sites: 40RANDOMIZED, TRIPLE, TREATMENT

LENZ Therapeutics, Inc.

Signal Score

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research